Cases Report on Innovative Drug-Delivery System Containing Paclitaxel for Treating Canine Gliomas
Authors:
Open Access
- 26 December 2024
- journal article
- Published by Gavin Publishers in Annals of Case Reports
- Vol. 9 (6)
Abstract
Glioblastomas in humans remain highly lethal, with a median survival of 12-14 months despite available treatments like surgery, radiotherapy, and chemKeywords
This publication has 44 references indexed in Scilit:
- Comparison of paclitaxel solid dispersion and polymeric micelles for improved oral bioavailability and in vitro anti-cancer effectsMaterials Science and Engineering: C, 2019
- Microfragmented human fat tissue is a natural scaffold for drug delivery: Potential application in cancer chemotherapyJournal of Controlled Release, 2019
- Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylindersVeterinary Medicine and Science, 2018
- Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue in Dogs with Spontaneous Osteoarthritis: Safety, Feasibility, and Clinical OutcomesStem Cells Translational Medicine, 2018
- New Treatment Modalities for Brain Tumors in Dogs and CatsVeterinary Clinics of North America: Small Animal Practice, 2014
- Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progressionJournal of Neuro-Oncology, 2007
- Mesenchymal stem cells as trophic mediatorsJournal of Cellular Biochemistry, 2006
- Local Intracerebral Administration of Paclitaxel with the Paclimer® Delivery System: Toxicity Study in a Canine ModelJournal of Neuro-Oncology, 2005
- Intracavitary Chemotherapy (Paclitaxel/Carboplatin Liquid Crystalline Cubic Phases) for Recurrent Glioblastoma – Clinical ObservationsJournal of Neuro-Oncology, 2005
- Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularizationCancer Immunology, Immunotherapy, 2004